Gazella Biotech
Biotechnology company focused on developing advanced therapies for metabolic diseases, with a primary target of obesity. The company emphasizes technologies for selective targeting of brain regions that regulate metabolism to minimize off-target side effects and aims to translate research into accessible treatments.
Industries
Nr. of Employees
small (1-50)
Gazella Biotech
Avenida de Barcelona 7, 15706 Santiago de Compostela
Products
Preclinical brain‑targeted therapies for metabolic diseases
Preclinical development programs that apply selective brain-targeting technologies to modulate hypothalamic pathways regulating metabolism, aiming to treat obesity and related metabolic disorders.
Preclinical brain‑targeted therapies for metabolic diseases
Preclinical development programs that apply selective brain-targeting technologies to modulate hypothalamic pathways regulating metabolism, aiming to treat obesity and related metabolic disorders.
Expertise Areas
- Metabolic disease therapeutics
- Targeted central nervous system delivery
- Extracellular vesicle–based delivery
- Preclinical in vivo obesity models
Key Technologies
- Small extracellular vesicles (sEVs)
- Hypothalamic AMPK modulation
- Targeted CNS delivery methods
- Rodent obesity models
News & Updates
Website notice indicating forthcoming significant news or updates.
Review discussing hypothalamic small extracellular vesicles as potential modulators of energy balance and obesity.
Preclinical study reporting that targeted delivery of AMPKα1 modulators via small extracellular vesicles promotes weight loss in leptin receptor–deficient mice.
Perspective on hypothalamic AMPK as a therapeutic target for disorders of energy balance.
Study showing that targeting hypothalamic AMPKα1 via small extracellular vesicles corrects obesity through activation of brown adipose tissue.
Website notice indicating forthcoming significant news or updates.
Review discussing hypothalamic small extracellular vesicles as potential modulators of energy balance and obesity.
Preclinical study reporting that targeted delivery of AMPKα1 modulators via small extracellular vesicles promotes weight loss in leptin receptor–deficient mice.
Perspective on hypothalamic AMPK as a therapeutic target for disorders of energy balance.
Study showing that targeting hypothalamic AMPKα1 via small extracellular vesicles corrects obesity through activation of brown adipose tissue.